Pharmaceutical development and manufacturing services provider Molecular Profiles is set to host a seminar in the UK focused on overcoming biological barriers in drug development.
The UK-based company, a subsidiary of Columbia Laboratories, will launch the New Year by welcoming pharmaceutical executives and scientists from across the globe to the two-day conference that aims to give an overview on the latest research in drug targeting and delivery for all routes of administration.
Keynote speakers already confirmed for the industry-led event include Professor Clive Wilson, Professor Jonathan Hadgraft, Professor Ijeoma Uchegbu and Professor Randy Mrsny.
Molecular Profiles’ chief technical officer Dr Robert Harris said: “We wanted to build upon the success of our event two years ago and mark the start of an exciting phase in the growth of our company with the opening of our new GMP facility by focussing on one of the key challenges in drug product development – overcoming the challenges of achieving bioavailability in the human body.
“The presentations will cover all aspects of drug delivery, from targeting to specific cells and locations in the body, to the advances in efficient delivery of drugs into the body.
“Our aim is to provide insight into these key areas of pharmaceutical research to help stimulate discussion and increase our knowledge and that of our attendees,” added Robert.
The conference is the second of its kind hosted by Molecular Profiles and will be held at the Belfry Hotel in Nottingham 21st – 22nd January 2014.
Attendees will be given a tour of Molecular Profiles’ new clinical manufacturing facility, which opened last year prior to the company being acquired by Columbia Laboratories, a Boston-based company with a rich heritage in drug development.
Working with leading pharmaceutical companies across the globe, Molecular Profiles specialises in advanced characterisation, pharmaceutical product development, clinical trials manufacturing and analytical support. The company prides itself in its specialist knowledge in development of formulations for challenging molecules.
Its new clinical manufacturing facility enables the company to manufacture a range of dosage forms such as solids, liquids, semi-solids and inhaled products, including the capability for manufacture of highly potent compounds.
To attend the event, contact Ailsa Pearson at Molecular Profiles | +44 (0) 115 871 8887 | email@example.com |